PATENT CLAIM ANALYSIS

Application Number: 16103830
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "248000"]

Abstract:
Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

Claim (Index 15):
The method of  claim 13 , wherein the condition comprises the metabolic-related condition comprising a trimethylaminuria (TMAU) condition associated with the at least one of TMA, TMAO, and derivatives thereof, and wherein administering to the patient with the condition comprises administering, to the patient with the TMAU condition, the therapeutically effective amount of the compound for inhibiting the CntA enzymes of the microorganisms from the at least one of Firmicutes (phylum) and Proteobacteria (phylum).

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.58537
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15610145', '14866398', '15366940', '15605437', '13915299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7281444104832668
- 35 USC 102 Novelty (BERT): 0.485644465259337
- Combined Prediction Score: 0.7038944159608739
- Mean Citation Score: 177.96008600000005
- Max Citation Score: 189.16028
- Similarity Product: 133.73217206923485

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test